The Hypoglycemia drugs in development market research report provides comprehensive information on the therapeutics under development for Hypoglycemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Hypoglycemia. Buy the report here.

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Hypoglycemia and features dormant and discontinued products.

GlobalData tracks 21 drugs in development for Hypoglycemia by 19 companies/universities/institutes. The top development phase for Hypoglycemia is preclinical with eight drugs in that stage. The Hypoglycemia pipeline has 21 drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Hypoglycemia pipeline products market are: LATITUDE Pharmaceuticals, Protheragen and MBX Biosciences Inc.

The key targets in the Hypoglycemia pipeline products market include Glucagon Receptor (GL R or GCGR), Glucagon Like Peptide 1 Receptor (GLP1R), and Insulin Receptor (IR or CD220 or INSR or EC 2.7.10.1).

The key mechanisms of action in the Hypoglycemia pipeline product include Glucagon Receptor (GL R or GCGR) Agonist with nine drugs in Pre-Registration. The Hypoglycemia pipeline products include five routes of administration with the top ROA being Subcutaneous and six key molecule types in the Hypoglycemia pipeline products market including Recombinant Peptide, and Synthetic Peptide.

Hypoglycemia overview

Hypoglycemia is a condition characterized by an abnormally low level of blood sugar (glucose). Symptoms of hypoglycemia include tachycardia; anxiety; shaking; irritability; and feelings of hunger, weakness, tiredness, dizziness, headache, confusion, and trouble concentrating. Risk factors include drug or alcohol consumption, older age, longer duration of diabetes, renal disease, peripheral neuropathy, obesity, and cognitive dysfunction.

For a complete picture of Hypoglycemia’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.